Kaitlyn D’Onofrio

DocwireNews

The use of artificial intelligence (AI) in health care is becoming more widespread, but how patients feel about it is a question up for debate. A new study found that when it comes to <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/which-are-the-most-common-types-of-cancer/">skin cancer</a> screening, patients may be receptive to its use.This was a qualitative study that used a grounded theory approach to semistructured interview analysis. A total of 48 <a href="https://www.docwirenews.com/blog/what-is-the-future-of-remote-patient-monitoring-rpm/">patients</a> were included in the study, which was conducted in general dermatology clinics at the Brigham and Women&rsquo;s Hospital and melanoma clinics at the Dana-Farber Cancer Institute. Two researchers conducted independent interviews regarding skin cancer screening with interrater reliability measurement. Code frequency was analyzed using reconciled codes. The primary outcome measures were AI intelligence concept, perceived benefits and risks of AI, strengths and weaknesses of AI, AI implementation, response to conflict between human and AI clinical decision-making, and recommendation for or against AI.<h2>Is AI the Future of Skin Cancer Screening?</h2>Just over half of patients (n=26, 54%) were female, and the mean age (SD) was 53.3 (21.7) years. A third of patients (n=16, 33%) had a history of <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/analyzing-partner-comfort-in-performing-skin-self-examinations-for-melanoma-survivors/">melanoma</a>, another third had a history of nonmelanoma skin cancer only, and the remaining third had no skin cancer history. Half of patients (n=24) were interviewed about a direct-to-patient AI tool, and the other half were asked about a clinician decision-support AI tool. The two coding teams had interrater reliability ratings of &kappa;&thinsp;=&thinsp;0.94 and &kappa;&thinsp;=&thinsp;0.89. Patients tended to think of AI of how it pertained to cognition; the main benefits they reported were increased diagnostic speed (n=29, 60%) and health care access (n=29, 60%), while the most common risk was increased patient anxiety (n=19, 40%). The greatest perceived strength of AI was more accurate diagnosis (n=33, 69%), while the greatest perceived weakness was less accurate diagnosis (n=41, 85%). The overarching theme observed in the interviews was the significance of symbiosis between humans and AI (n=45, 94%). The primary response to conflict between human-AI clinical decision-marking was seeking biopsy (n=32, 67%). Three-quarters of patients (n=36) said they would recommend AI to family and friends.The study was published in <a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2762711">JAMA Dermatology</a>.&ldquo;In this qualitative study, patients appeared to be receptive to the use of AI for skin cancer screening if implemented in a manner that preserves the integrity of the human physician-patient relationship,&rdquo; concluded the study authors.

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

Are Patients Receptive to AI Use for Skin Cancer Screening?

Skin Cancer

The use of artificial intelligence (AI) in health care is becoming more widespread, but how patients feel about it is a question up for debate. A new study found that when it ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe